{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:24:40Z","timestamp":1794003880405,"version":"4.8.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ijgc.2026.104948","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T23:36:14Z","timestamp":1786145774000},"page":"104948","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploring the association between homologous recombination status, KELIM, and resectability in high-grade serous ovarian cancer"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-3300-2989","authenticated-orcid":false,"given":"Mayerly","family":"Castrill\u00f3n S\u00e1nchez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1282-5379","authenticated-orcid":false,"given":"Gabriel","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrie","family":"Shahbazian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4323-3854","authenticated-orcid":false,"given":"Reitan","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Bernard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8739-3879","authenticated-orcid":false,"given":"Basile","family":"Tessier-Cloutier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8605-5472","authenticated-orcid":false,"given":"Lucy","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4110-7595","authenticated-orcid":false,"given":"Shuk On Annie","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ijgc.2026.104948_bib1","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41571-024-00881-3","article-title":"Global epidemiology of epithelial ovarian cancer","volume":"21","author":"Webb","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"18","key":"10.1016\/j.ijgc.2026.104948_bib2","doi-asserted-by":"crossref","first-page":"E615","DOI":"10.1503\/cmaj.240095","article-title":"Projected estimates of cancer in Canada in 2024","volume":"196","author":"Brenner","year":"2024","journal-title":"CMAJ: Can Med Assoc J."},{"issue":"2","key":"10.1016\/j.ijgc.2026.104948_bib3","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3802\/jgo.2015.26.2.87","article-title":"FIGO\u2019s staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication","volume":"26","author":"Prat","year":"2015","journal-title":"J Gynecol Oncol"},{"issue":"12","key":"10.1016\/j.ijgc.2026.104948_bib4","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1038\/s41588-022-01230-9","article-title":"The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer","volume":"54","author":"Garsed","year":"2022","journal-title":"Nat Genet."},{"issue":"5","key":"10.1016\/j.ijgc.2026.104948_bib5","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S1470-2045(19)30029-4","article-title":"Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial","volume":"20","author":"Moore","year":"2019","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104948_bib6","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1186\/s12885-025-14423-2","article-title":"Homologous recombination deficiency (HRD) tests for ovarian cancer: a multicenter French phase II study (HERO)","volume":"25","author":"Leman","year":"2025","journal-title":"BMC Cancer"},{"issue":"15_suppl","key":"10.1016\/j.ijgc.2026.104948_bib7","doi-asserted-by":"crossref","first-page":"5568","DOI":"10.1200\/JCO.2021.39.15_suppl.5568","article-title":"Correlation of HRD status with clinical and survival outcomes in patients with advanced-stage ovarian cancer","volume":"39","author":"Sims","year":"2021","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ijgc.2026.104948_bib8","first-page":"906","article-title":"Complete cytoreductive surgery, the key factor for survival in advanced ovarian cancer","volume":"41","author":"Esteves-Krasteva","year":"2020","journal-title":"Experience of an intermediate volume hospital"},{"issue":"6","key":"10.1016\/j.ijgc.2026.104948_bib9","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cncr.24149","volume":"115","author":"du Bois","year":"2009","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104948_bib10","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.ygyno.2013.05.040","article-title":"Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis","volume":"130","author":"Chang","year":"2013","journal-title":"Gynecol Oncol"},{"issue":"7","key":"10.1016\/j.ijgc.2026.104948_bib11","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1200\/JCO-24-02589","article-title":"Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: ASCO guideline update","volume":"43","author":"Gaillard","year":"2025","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ijgc.2026.104948_bib12","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1136\/ijgc-2019-000222","article-title":"Measuring response to neoadjuvant chemotherapy in high-grade serous tubo-ovarian carcinoma: an analysis of the correlation between CT imaging and chemotherapy response score","volume":"29","author":"McNulty","year":"2019","journal-title":"Int J Gynecol Cancer"},{"issue":"10","key":"10.1016\/j.ijgc.2026.104948_bib13","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.39893","article-title":"Utilization of primary cytoreductive surgery for advanced-stage ovarian cancer","volume":"7","author":"Bercow","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"17","key":"10.1016\/j.ijgc.2026.104948_bib14","doi-asserted-by":"crossref","first-page":"4625","DOI":"10.1158\/1078-0432.CCR-20-0054","article-title":"CA-125 ELIMination rate constant K (KELIM) is a marker of chemosensitivity in patients with ovarian cancer: results from the Phase II CHIVA trial","volume":"26","author":"You","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104948_bib15","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ygyno.2013.05.013","article-title":"The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: data from Calypso trial (a GINECO-GCIG study)","volume":"130","author":"You","year":"2013","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104948_bib16","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1186\/s12885-024-12252-3","article-title":"CA-125 elimination rate constant K (KELIM) as a promising predictor of complete cytoreduction after neoadjuvant chemotherapy in advanced ovarian cancer patients: a retrospective study from two Chinese hospitals","volume":"24","author":"Li","year":"2024","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104948_bib17","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.canlet.2015.08.028","article-title":"High response rates to neoadjuvant platinum-based therapy in ovarian cancer patients carrying germ-line BRCA mutation","volume":"369","author":"Gorodnova","year":"2015","journal-title":"Cancer Lett"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104948_bib18","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S1470-2045(20)30591-X","article-title":"Objective responses to first-line neoadjuvant carboplatin\u2013paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial","volume":"22","author":"Morgan","year":"2021","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104948_bib19","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1136\/ijgc-2023-004872","article-title":"Clinical impact of CA-125 ELIMination rate constant K (KELIM) on surgical strategy in advanced serous ovarian cancer patients","volume":"34","author":"Bouvarel","year":"2024","journal-title":"Int J Gynecol Cancer"},{"issue":"6","key":"10.1016\/j.ijgc.2026.104948_bib20","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.3390\/cancers14061511","article-title":"Distinct genomic profiles are associated with treatment response and survival in ovarian cancer","volume":"14","author":"de Witte","year":"2022","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.ijgc.2026.104948_bib21","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1158\/1078-0432.CCR-09-2758","article-title":"Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors","volume":"16","author":"Mukhopadhyay","year":"2010","journal-title":"Clin Cancer Res"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26004792?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26004792?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:32:43Z","timestamp":1794000763000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X26004792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":21,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S1048891X26004792"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104948","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring the association between homologous recombination status, KELIM, and resectability in high-grade serous ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104948","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of European Society of Gynaecological Oncology and the International Gynecologic Cancer Society.","name":"copyright","label":"Copyright"}],"article-number":"104948"}}